key: cord-0335812-orr267fh authors: Yu, Jingyou; Collins, Natalie D.; Mercado, Noe B.; McMahan, Katherine; Chandrashekar, Abishek; Liu, Jinyan; Anioke, Tochi; Chang, Aiquan; Giffin, Victoria M.; Hope, David L.; Sellers, Daniel; Nampanya, Felix; Gardner, Sarah; Barrett, Julia; Wan, Huahua; Velasco, Jason; Teow, Elyse; Cook, Anthony; Van Ry, Alex; Pessaint, Laurent; Andersen, Hanne; Lewis, Mark G.; Hofer, Christian; Burke, Donald S.; Barkei, Erica K.; King, Hannah A.D.; Subra, Caroline; Bolton, Diane; Modjarrad, Kayvon; Michael, Nelson L.; Barouch, Dan H. title: Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery Against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques date: 2021-09-14 journal: bioRxiv DOI: 10.1101/2021.09.13.460191 sha: 75ae3081f789e7c5ea72d47daf6022cbb06686f0 doc_id: 335812 cord_uid: orr267fh Live oral vaccines have been explored for their protective efficacy against respiratory viruses, particularly for adenovirus serotypes 4 and 7. The potential of a live oral vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), however, remains unclear. In this study, we assessed the immunogenicity of live SARS-CoV-2 delivered to the gastrointestinal tract in rhesus macaques and its protective efficacy against intranasal and intratracheal SARS-CoV-2 challenge. Post-pyloric administration of SARS-CoV-2 by esophagogastroduodenoscopy resulted in limited virus replication in the gastrointestinal tract and minimal to no induction of mucosal antibody titers in rectal swabs, nasal swabs, and bronchoalveolar lavage. Low levels of serum neutralizing antibodies were induced and correlated with modestly diminished viral loads in nasal swabs and bronchoalveolar lavage following intranasal and intratracheal SARS-CoV-2 challenge. Overall, our data show that post-pyloric inoculation of live SARS-CoV-2 is weakly immunogenic and confers partial protection against respiratory SARS-CoV-2 challenge in rhesus macaques. Importance SARS-CoV-2 remains a global threat, despite the rapid deployment but limited coverage of multiple vaccines. Alternative vaccine strategies that have favorable manufacturing timelines, greater ease of distribution and improved coverage may offer significant public health benefits, especially in resource-limited settings. Live oral vaccines have the potential to address some of these limitations; however no studies have yet been conducted to assess the immunogenicity and protective efficacy of a live oral vaccine against SARS-CoV-2. Here we report that oral administration of live SARS-CoV-2 in non-human primates may offer prophylactic benefits, but that formulation and route of administration will require further optimization. greater ease of distribution and improved coverage may offer significant public health benefits, 48 especially in resource-limited settings. Live oral vaccines have the potential to address some of 49 these limitations; however no studies have yet been conducted to assess the immunogenicity and cost-effective. The replicating feature of live viruses can allow for administration of a lower dose 79 to achieve immunity. As such, oral vaccines may be preferable in resource-limited settings. 80 To date, several human oral vaccines have been licensed that contain live viruses. The US 81 Department of Defense (DoD) and National Institutes of Health (NIH) developed co-82 administered live oral vaccines against adenovirus serotypes 4 and 7 (Ad4 and Ad7) in the 1970s 83 (9, 10) and again in 2011 when the vaccine was re-formulated (11-13). These two vaccines 84 contain wild-type virus with an enteric coating to protect against degradation from the low pH of 85 gastric acid as they pass through to the lower GI tract (12, 14, 15 However, we did not observe virus in serum, saliva, bronchoalveolar lavage (BAL) or nasal 120 swabs (NS) (data not shown). On day 1, vaccinated animals had a median 3.49 log 10 viral copies 121 per gram stool, whereas the sham animals had no detectable virus (P<0.00001, two-sided Mann-122 Whitney tests) (Fig. 1E) . These data suggest that the virus inoculum was rapidly excreted with 123 limited virus replication in the GI tract. Four weeks after vaccination, we observed low serum pseudovirus neutralizing antibody 127 (NAb) titers in 7 of 9 vaccinated macaques (Fig. 2) , whereas the sham animals had undetectable 128 NAb titers. NAb titers in mucosal specimens, including NS, BAL, RS, and stool, were below the 129 limit of detection (data not shown). We assessed T cell responses in peripheral blood A strategic approach to COVID-19 vaccine R&D Approaches and Challenges in SARS-CoV-2 Vaccine 365 Development Regional specialization within the intestinal immune system Mucosal immunity and vaccines Replicating and non-replicating viral vectors for vaccine development. Current 370 opinion in biotechnology Mucosal vaccines: the promise and the challenge Current state and challenges in developing oral 374 vaccines Prospects for oral replicating adenovirus-vectored vaccines Immunization with Live Types 7 and 4 Adenovirus Vaccines. I. Safety and Potency of Adenovirus Type 7 Vaccine in Humans. The Journal of 379 Infectious Diseases CONTROL OF RESPIRATORY 381 DISEASE IN RECRUITS WITH TYPES 4 AND 7 ADENOVIRUS VACCINES A phase 3, randomized, double-blind, placebo-controlled study of the 384 safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine A double-blind, placebo-controlled study of the safety and immunogenicity of live, 387 oral type 4 and type 7 adenovirus vaccines in adults Safety evaluation of adenovirus 389 type 4 and type 7 vaccine live, oral in military recruits Adenovirus Vaccines in the U Acute Respiratory Illness of Adenovirus (RI-APC-ARD) Etiology. American Journal of Public Health 394 and the Nations Health Live Oral Adenovirus Type 4 and Type 7 Vaccine Induces Durable Antibody 396 Response Polio vaccination: past, present and 398 future Polio eradication-lessons from the past and future perspective The rotavirus vaccine development pipeline Rotavirus vaccines: current prospects and future challenges Tissue distribution of ACE2 protein, the functional receptor for SARS 406 coronavirus. A first step in understanding SARS pathogenesis Comparison of Subgenomic and Total RNA in SARS-CoV-2-Challenged Rhesus 409 Virological assessment of hospitalized patients with COVID-2019 DNA vaccine protection against SARS-CoV-2 in rhesus macaques Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. 415 Potential intestinal infection and faecal-oral transmission 417 of SARS-CoV-2 Evidence for Gastrointestinal Infection of SARS-CoV-2 The Gastrointestinal Tract Is an Alternative Route for SARS-CoV-2 Infection in a 421 Nonhuman Primate Model SARS-CoV-2 productively infects human gut enterocytes TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal 425 enterocytes SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a 427 Clinically Proven Protease Inhibitor SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19 SARS-CoV-2 infection protects against rechallenge in rhesus macaques Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in 433 Pseudovirus Neutralization Assays Comparison of Subgenomic and Total RNA in SARS-CoV-2 Challenged Rhesus 435 Macaques Virological assessment of hospitalized patients with COVID-2019